High RDW After Iron Therapy: Why It May Rise First

Categories
Articles
Iron Deficiency Lab Interpretation 2026 Update Patient-Friendly

An early RDW rise after treating iron deficiency often reflects recovery, not failure. The useful question is whether haemoglobin, reticulocytes, MCV, and iron stores are moving in the right direction beside it.

📖 ~11 minutes 📅
📝 Published: 🩺 Medically Reviewed: ✅ Evidence-Based
⚡ Quick Summary v1.0 —
  1. High RDW often rises during the first 1-3 weeks of effective iron treatment because older microcytes coexist with newly produced, larger red cells.
  2. RDW-CV is commonly reported as 11.5-14.5%, but each laboratory sets its own interval and an isolated result is not an emergency.
  3. Reticulocytes usually increase within 3-7 days when marrow has iron available; they are naturally larger than mature red cells.
  4. Haemoglobin response of at least 10 g/L within about 2 weeks strongly supports a response to oral iron in iron-deficiency anaemia.
  5. Ferritin can be misleading during infection or inflammatory disease because it rises as an acute-phase protein; CRP and transferrin saturation add context.
  6. Reassessment is needed when haemoglobin falls, symptoms worsen, reticulocytes remain low, or RDW stays high after the CBC has otherwise normalised.
  7. Oral iron timing matters: calcium, antacids, tea, and coffee can reduce absorption, while alternate-day dosing helps some people tolerate treatment.
  8. Urgent care is appropriate for chest pain, fainting, severe breathlessness at rest, black tarry stool, or rapid ongoing blood loss—not for a high RDW alone.

Why a high RDW can appear before iron therapy looks successful

A high RDW can rise first after iron therapy because the circulation briefly contains two differently sized red-cell populations: older iron-deficient microcytes and newly made cells with more normal volume. This pattern is most often seen from roughly day 7 through week 3, even while haemoglobin begins to recover. As of July 23, 2026, I would not call this treatment failure from RDW alone. Kantesti AI is an AI blood test analyzer that reads RDW alongside haemoglobin, MCV, reticulocytes, ferritin, and the date treatment started.

High RDW recovery illustrated by mixed small and newly normal-sized cellular elements
Figure 1: Mixed red-cell sizes explain why RDW can rise during early iron recovery.

RDW measures variation in red-cell size, not the amount of iron in your body. RDW-CV is calculated from the spread of cell volumes relative to the MCV, so it can increase when two populations overlap—even if neither population is alarming by itself. Our complete RDW guide explains why the laboratory flag must be read with the rest of the CBC.

The first reassuring sign is usually a reticulocyte response, not a lower RDW. Reticulocytes begin appearing in greater numbers about 3-7 days after effective treatment, and they are roughly 10-15% larger than mature erythrocytes. That temporary size contrast can widen the RDW distribution before enough old microcytes are cleared.

In my 15 years of clinical practice, a patient with haemoglobin rising from 92 to 104 g/L and RDW moving from 16.8% to 19.1% over 2 weeks is often recovering exactly as hoped. Dr. Thomas Klein’s practical rule is simple: an RDW increase paired with improving haemoglobin, rising reticulocytes, and stable symptoms is usually a transition signal, not a setback.

What RDW-CV and RDW-SD actually measure

RDW-CV commonly has an adult reference interval near 11.5-14.5%, while RDW-SD is often about 39-46 fL, but ranges differ by analyser and laboratory. A result above range means red-cell volumes are more varied than expected; it does not identify a cause on its own.

High RDW laboratory concept showing varied cellular element sizes across a clinical field
Figure 2: RDW reflects the width of the red-cell size distribution, not iron stores alone.

RDW-CV can look more dramatic when MCV is low because MCV appears in its calculation. In iron deficiency with an MCV of 72 fL, a modest absolute spread in cell volumes may yield a higher RDW-CV than the same spread at an MCV of 90 fL. That mathematical quirk explains some of the anxiety around an iron deficiency recovery blood test.

RDW-SD is an absolute width measured in femtolitres and is less dependent on MCV. Not every laboratory reports it, and serial comparison is most useful when the same method is used each time. For context on the accompanying indices, see what a CBC includes.

A high RDW of 18% with haemoglobin 120 g/L can be less concerning than an RDW of 14% with haemoglobin 78 g/L and active symptoms. The severity of anaemia, its direction of travel, and the cause of iron loss carry more clinical weight than the RDW flag.

Typical RDW-CV interval About 11.5-14.5% Cell-size variation is within that laboratory's expected adult interval.
Mildly high RDW-CV About 14.6-17.0% Often occurs with early iron deficiency, recovery, B12/folate deficiency, or mixed red-cell populations.
Clearly high RDW-CV About 17.1-20.0% Supports marked anisocytosis; interpret with MCV, haemoglobin, reticulocytes, and smear findings.
Very high RDW-CV Above 20.0% Not an emergency by itself, but persistent elevation merits a cause-based review and sometimes a blood-film examination.

The red-cell timeline after starting iron treatment

Effective oral iron commonly produces a reticulocyte rise within 3-7 days, a measurable haemoglobin increase by 2-4 weeks, and a slower MCV recovery over several weeks. RDW may peak in the middle of that sequence because the oldest microcytes remain in circulation for months.

Iron recovery pathway from intestinal absorption to new cellular element production
Figure 3: Iron reaches marrow before older microcytes have left the circulation.

Mature red cells circulate for about 120 days, so the CBC cannot become uniform overnight. Iron treatment changes the cells produced today; it does not resize microcytes made 6 weeks earlier. The mixed population is especially visible after severe deficiency, when baseline MCV is below 75 fL.

A haemoglobin increase of at least 10 g/L after 2 weeks is a useful early response benchmark in adults taking oral iron. The British Society of Gastroenterology guideline uses that rise as strong evidence of iron-deficiency anaemia responsiveness (Snook et al., 2021). Kantesti AI compares dated panels rather than treating a single post-treatment CBC as a verdict.

The pace differs after intravenous iron, pregnancy, kidney disease, or continued menstrual loss. A person receiving erythropoiesis-stimulating therapy may show reticulocyte changes quickly, whereas untreated coeliac disease or ongoing bleeding can blunt the rise. The iron studies reference guide helps separate supply, transport, and storage markers.

How old microcytes and new cells create the RDW increase

The RDW increase after iron supplements is usually a two-population effect: small pre-treatment microcytes remain while newer reticulocytes and normocytes enter circulation. A blood-film review, when performed, may describe this as anisocytosis or a dimorphic red-cell population.

Microscopic cellular element field with smaller older cells and larger newer cells
Figure 4: Older microcytes coexist with newer cells during the early treatment transition.

Reticulocytes are larger because they are newly released marrow cells that still contain residual RNA. Their normal maturation over 1-2 days in blood reduces their size, but the initial influx is enough to alter the distribution on an automated analyser. This is why the reticulocyte count adds meaning that RDW alone cannot provide.

MCV may remain low even while iron treatment is working. An MCV of 76 fL at week 2 can coexist with a healthy reticulocyte response and a haemoglobin increase of 12 g/L, because MCV averages every circulating cell. For more on these linked indices, read our reticulocyte and haematology markers guide.

A useful nuance: some people begin treatment with a normal MCV but a high RDW because deficiency developed gradually. In that situation, the new cells may not change MCV much at all, while RDW still reflects the uneven age and size mix.

Which CBC changes matter more than RDW after treatment

Haemoglobin direction, reticulocyte production, MCV trend, and symptoms matter more than RDW after iron treatment. A rising RDW with haemoglobin increasing by 10-20 g/L over 2-4 weeks is generally more reassuring than a normal RDW with falling haemoglobin.

Automated haematology analyser processing a cellular element sample for RDW assessment
Figure 5: Automated CBC analysis reports RDW alongside more decisive recovery markers.

Haemoglobin usually tells us whether oxygen-carrying capacity is recovering. Adult reference intervals vary, but many laboratories use roughly 120-160 g/L for non-pregnant women and 130-170 g/L for men. A value can improve meaningfully before it enters range, so percentage change and symptoms deserve attention.

Reticulocyte haemoglobin content, reported as RET-He or CHr by some analysers, can respond earlier than ferritin. A low value often indicates iron-restricted erythropoiesis; a rise within 1-2 weeks suggests iron is reaching marrow. Sudden, implausible changes should prompt a lab delta-check review, especially if samples came from different laboratories.

Platelets can also fall toward baseline as iron deficiency improves. Mild reactive thrombocytosis sometimes accompanies iron deficiency, although a persistently high platelet count above 450 × 10⁹/L needs its own assessment. RDW does not explain that finding away.

What an expected RDW pattern looks like over the first 12 weeks

An expected recovery pattern is rising reticulocytes in week 1, improving haemoglobin by weeks 2-4, a temporary high RDW in weeks 1-3, and gradual narrowing of RDW over the next 1-3 months. Individual timing varies with starting haemoglobin, dose, absorption, and ongoing losses.

Clinical process arrangement showing iron therapy stages and sequential laboratory samples
Figure 6: Treatment response unfolds in stages rather than as a single normal CBC.

At baseline, iron deficiency often shows low ferritin, low transferrin saturation, low or falling MCV, and high RDW. Serum iron alone can fluctuate substantially with time of day and recent supplements, which is why it is a poor solo measure of progress. A ferritin below 15 µg/L is highly specific for depleted stores in an otherwise well adult.

By week 2, an improving CBC can still look visually untidy. I have seen patients stop 65 mg elemental iron daily because their RDW rose from 15.2% to 17.6%, despite haemoglobin climbing from 98 to 110 g/L. Their concern was understandable, but stopping at that point can prolong deficiency; our iron supplement timing guide covers safer retest intervals.

By 8-12 weeks, persistent high RDW deserves a closer look if haemoglobin and MCV have normalised. Ongoing alcohol exposure, B12 or folate deficiency, liver disease, haemolysis, and a mixed anaemia can all maintain size variation. That is a reassessment question, not automatically a failure of iron.

Dose, schedule, and absorption can change the recovery pattern

Most adults are started on one daily oral iron preparation, often providing about 40-100 mg elemental iron, but tolerability and absorption determine whether that prescription works. Taking more tablets does not always create a faster haemoglobin rise because hepcidin temporarily reduces absorption after a dose.

Targeted iron nutrition scene with lentils, citrus, ferrous tablets and a laboratory sample
Figure 7: Iron dose timing and food interactions can influence early laboratory recovery.

Ferrous sulfate 200 mg contains about 65 mg elemental iron, while product strengths vary widely by salt and country. The British Society of Gastroenterology advises one tablet daily of ferrous sulfate, fumarate, or gluconate initially; if not tolerated, every-other-day use is a reasonable alternative (Snook et al., 2021).

Tea, coffee, calcium supplements, and antacids can reduce non-haem iron absorption when taken close to the dose. A 2-hour separation is a practical starting point, although prescribed medicines always take priority and some people need pharmacist advice. Our comparison of iron bisglycinate and sulfate explains why tolerability differs.

Constipation, nausea, and dark stool are common effects; black tarry stool with weakness or dizziness is different and needs prompt medical assessment. Dr. Thomas Klein advises patients not to use RDW as a reason to double their dose. Better adherence to a tolerable schedule beats an aggressive regimen abandoned after 5 days.

Why ferritin may not confirm recovery when RDW is high

Ferritin can rise during infection, obesity, liver disease, or inflammatory conditions even when iron available to marrow remains low. When RDW is high after treatment, ferritin should be interpreted with CRP, transferrin saturation, CBC direction, and the clinical setting.

Ferritin protein storing iron atoms within a marrow cellular environment
Figure 8: Ferritin stores iron but also rises as part of the acute-phase response.

A ferritin below 15 µg/L strongly supports absent iron stores, while values below 30 µg/L commonly support iron deficiency in routine clinical practice. In active inflammation, a ferritin below 100 µg/L with transferrin saturation below 20% may still be compatible with iron-restricted erythropoiesis, depending on the condition.

Transferrin saturation below 20% indicates that relatively little circulating iron is available for red-cell production. Kantesti is an AI blood test interpretation platform that evaluates ferritin and transferrin saturation as a pair, then checks whether CRP or liver enzymes may distort the storage signal. See our guide to ferritin and CRP for the common inflammatory pattern.

Intravenous iron can raise ferritin sharply soon after infusion, so checking stores too early can be misleading. Many clinicians wait at least 4-8 weeks after intravenous replacement before making a durable judgement about ferritin, unless a specialist has set a different monitoring plan.

When a persistent high RDW needs reassessment rather than patience

A high RDW needs reassessment when haemoglobin is falling or unchanged after 2-4 weeks of adherent treatment, reticulocytes are low, MCV rises unexpectedly, or symptoms progress. RDW itself is not dangerous, but it can expose an incomplete or incorrect explanation for anaemia.

Medical comparison of resolving mixed cell sizes versus persistent variable cellular elements
Figure 9: Recovery and non-response patterns differ when CBC trends are viewed together.

No haemoglobin rise of about 10 g/L by week 2 should trigger a conversation about adherence, absorption, diagnosis, and ongoing loss. This threshold is a screening signal rather than a hard rule; severe inflammation, chronic kidney disease, and a low starting reticulocyte count may change the pace. The AGA guidance stresses confirming iron deficiency and investigating a plausible source rather than treating numbers indefinitely (Ko et al., 2020).

A rising MCV above 100 fL after iron starts is not explained by iron recovery alone. B12 deficiency, folate deficiency, alcohol, hypothyroidism, medication effects, reticulocytosis, and marrow disorders belong on the differential. A soluble transferrin receptor test can be useful when ferritin is difficult to interpret.

Haemolysis can also broaden RDW because marrow releases more reticulocytes while red cells are removed early. High LDH, unconjugated bilirubin, and low haptoglobin are clues, but each can have other causes. This is one of those areas where context matters more than the number.

Testing mistakes that can make RDW after iron treatment confusing

Comparing CBCs from different laboratories, drawing at inconsistent intervals, and treating serum iron as a stable marker can make an expected recovery look abnormal. RDW is fairly stable analytically, but biological recovery and assay methods still matter.

Iron study laboratory still life with separated sample, centrifuge cup and timing tools
Figure 10: Consistent preparation prevents avoidable confusion in repeat iron studies.

Serum iron can change after a recent tablet and may vary across the day, so a high serum iron does not prove stores are replete. For an iron panel, clinicians often ask patients to follow the laboratory's instructions about fasting and supplements. Our TIBC preparation guide explains why those details alter interpretation.

Hydration can shift haemoglobin and haematocrit modestly through plasma-volume changes without altering red-cell production. A dehydrated sample may look more concentrated; an intravenous-fluid setting may look diluted. RDW is generally less influenced by hydration than haemoglobin, but it still should not be isolated from the clinical circumstances.

A blood film is not routinely required for every high RDW result. It becomes particularly helpful when there are flags for abnormal cell shapes, unexplained cytopenias, very high RDW above 20%, or disagreement between automated indices and the clinical picture.

Why treating the cause matters when RDW stays high

Iron replacement can correct the CBC temporarily, but RDW may remain high or recur if menstrual loss, gastrointestinal loss, low intake, malabsorption, or increased demand continues. Adults should not assume diet alone explains confirmed iron-deficiency anaemia without considering the whole history.

Clinical consultation scene reviewing iron loss causes with laboratory materials and stool test kit
Figure 11: Persistent iron deficiency requires investigation of the source as well as replacement.

Heavy menstrual bleeding is a frequent cause in premenopausal people, yet it does not exclude coeliac disease or gastrointestinal loss. Ferritin below 30 µg/L in the setting of fatigue and recurrent deficiency warrants a cause-focused history, including medication use, bowel symptoms, blood donation, and dietary restriction. See our review of low ferritin without heavy periods.

For men and postmenopausal women with iron-deficiency anaemia, gastrointestinal evaluation is commonly recommended unless there is an obvious alternative explanation. The AGA guideline supports bidirectional endoscopy in many such cases because occult gastrointestinal causes can be clinically silent (Ko et al., 2020). The decision is individual and should account for age, risk, and symptoms.

Pregnancy, adolescence, endurance sport, bariatric surgery, and frequent donation change the probability of different causes. A ferritin result should never be used to dismiss new abdominal pain, weight loss, altered bowel habit, or visible gastrointestinal bleeding.

When to repeat an iron deficiency recovery blood test

For uncomplicated oral iron treatment, repeating a CBC in about 2-4 weeks usually shows whether haemoglobin is responding, while ferritin is often more useful after haemoglobin correction or around 8-12 weeks. Testing every few days mainly captures noise and the early RDW transition.

Patient journey showing an olive-skinned hand organizing dated laboratory sample appointments
Figure 12: Planned repeat testing makes the recovery slope easier to interpret.

A 2-week CBC is particularly useful when baseline haemoglobin is below 100 g/L, symptoms are significant, pregnancy is involved, or absorption is uncertain. A 4-week check is reasonable for many stable adults with mild anaemia and good tolerance. The anemia pattern guide shows which companion values should be recorded each time.

Keep the same laboratory where possible and write down the elemental iron dose, schedule, missed doses, recent illness, menstrual timing, and blood donation. Those details can explain a 5-10 g/L haemoglobin shift that would otherwise look mysterious. Kantesti AI can organise dated values, but it cannot replace the clinician who knows your symptoms and examination findings.

Do not wait for a routine recheck if breathlessness at rest, chest pain, fainting, rapidly racing heartbeat, heavy ongoing bleeding, or black tarry stool develops. Those symptoms change the urgency regardless of whether RDW is 13% or 19%.

A practical way to read RDW, MCV, haemoglobin, and ferritin together

The most reassuring iron-recovery pattern is haemoglobin rising, reticulocytes present, MCV gradually increasing from a low baseline, and RDW temporarily high before narrowing. The least reassuring pattern is falling haemoglobin with persistently low iron availability and no reticulocyte response.

Precision haematology instrument portrait used for serial CBC and RDW analysis
Figure 13: Serial results are more informative when analysed as a connected pattern.

Pattern A: haemoglobin 88 to 101 g/L, MCV 70 to 73 fL, RDW 17% to 19%, and reticulocytes rising is compatible with early response. It says new cells are arriving faster than older microcytes are leaving. Comparing results side by side is safer than judging an isolated flag; our visit-to-visit comparison guide shows how to do that.

Pattern B: haemoglobin 105 to 103 g/L, MCV 78 to 77 fL, RDW 18% to 20%, ferritin 9 µg/L, and no treatment adherence suggests inadequate replacement or continued loss. The next step is usually not guessing a different diagnosis from RDW; it is checking dose, absorption, bleeding, and the original diagnosis.

Kantesti AI is an AI-powered blood test analysis tool** that can identify these linked trajectories across uploaded reports, including changes in units and reference ranges. Its results are best used to prepare focused questions for a GP, haematologist, obstetric team, or pharmacist.

Pregnancy, kidney disease, B12 deficiency, and other special contexts

Pregnancy, chronic kidney disease, inflammation, and combined B12 or folate deficiency can make a high RDW after iron therapy harder to interpret. In these settings, ferritin cutoffs, haemoglobin targets, and monitoring intervals may differ from routine adult care.

Watercolor marrow illustration showing iron-restricted and macrocytic cellular element pathways
Figure 14: Combined nutrient and chronic-disease patterns can keep RDW elevated longer.

During pregnancy, haemodilution lowers measured haemoglobin while iron demand rises, especially after the first trimester. Many guidelines use ferritin below 30 µg/L to identify iron deficiency in pregnancy, but local obstetric pathways should guide treatment and rechecks. A haemoglobin change without gestational age is incomplete information.

Chronic kidney disease can produce functional iron deficiency: ferritin may be normal or high while transferrin saturation is below 20%. Erythropoietin deficiency also reduces marrow output, so a low reticulocyte response is not interpreted the same way as in an otherwise healthy person. Our kidney disease stages guide provides the renal context.

B12 or folate deficiency can mask microcytosis by increasing cell size, leaving a normal MCV but a striking RDW. Camaschella’s review of iron-deficiency anaemia highlights that mixed deficiencies are a common reason indices fail to follow the textbook pattern (Camaschella, 2015).

Questions to take to your clinician when RDW remains high

Ask whether your haemoglobin response, reticulocyte count, ferritin, transferrin saturation, and source of iron deficiency fit one coherent story. A high RDW is most useful when it prompts a focused follow-up rather than a panicked medication change.

Bring the pre-treatment CBC and iron studies, not only the newest report. Ask: has haemoglobin increased by roughly 10 g/L within 2 weeks or by a meaningful amount at 4 weeks, and was my ferritin truly low before treatment? Kantesti's clinical validation information describes why trend interpretation requires both reference intervals and clinical oversight.

Ask whether persistent elevation could reflect B12, folate, thyroid, liver, kidney, haemolysis, or marrow factors rather than iron alone. If you have recurrent deficiency, ask what has been done to identify loss or malabsorption and whether a different iron formulation, intravenous iron, or specialist referral is appropriate. There is no universal RDW cutoff that answers those questions.

Kantesti’s medical content is reviewed with physician input, and our Medical Advisory Board supports a safety-first approach to unusual result patterns. The practical bottom line is reassuring but conditional: high RDW after iron therapy often reflects recovery first, provided the rest of the trajectory is improving.

Frequently Asked Questions

Can RDW go up after starting iron supplements?

Yes. RDW can rise during the first 1-3 weeks after starting effective iron treatment because newly produced reticulocytes and normal-sized red cells circulate beside older iron-deficient microcytes. Reticulocytes usually increase within 3-7 days, while old microcytes can remain for up to about 120 days. A rising RDW is generally reassuring when haemoglobin is increasing by about 10 g/L within 2 weeks and symptoms are stable or improving.

How long does RDW stay high after iron treatment?

RDW often remains high for several weeks and may take 1-3 months to narrow as older microcytes leave circulation. The exact duration depends on the starting MCV, severity of iron deficiency, continued blood loss, and whether treatment is absorbed. RDW should not be used as the only marker of recovery; haemoglobin, MCV, reticulocytes, ferritin, and transferrin saturation provide the fuller picture. Persistent RDW elevation after haemoglobin and MCV normalise deserves a clinician-led review for mixed nutrient deficiency, liver disease, alcohol exposure, haemolysis, or another cause.

Is an RDW of 18% dangerous after iron therapy?

An RDW of 18% is not dangerous by itself and does not require urgent treatment solely because of that number. Many laboratories use an RDW-CV upper limit near 14.5%, so 18% indicates pronounced variation in red-cell size. After iron therapy, it can reflect a normal mixture of older microcytes and newer cells. Urgency depends instead on haemoglobin level, active bleeding, chest pain, fainting, severe breathlessness, or rapidly worsening weakness.

Why is my MCV still low after taking iron?

MCV can remain low for weeks after iron treatment because it averages both new cells and older microcytes already circulating. Mature red cells live about 120 days, so iron therapy cannot immediately change the size of cells made before treatment. An MCV that rises gradually from 72 fL to 76 fL alongside a haemoglobin increase is often consistent with recovery. If MCV stays low and haemoglobin does not rise after 2-4 weeks, adherence, absorption, ongoing loss, thalassaemia trait, and the original diagnosis should be reassessed.

Should I stop iron if my RDW increases after treatment?

Do not stop prescribed iron solely because RDW increases during the first few weeks. A temporary RDW increase is expected when reticulocytes appear within 3-7 days and newer cells differ in size from existing microcytes. Contact the clinician who prescribed treatment if you have severe gastrointestinal effects, cannot take the dose, develop black tarry stool, or your haemoglobin fails to improve by roughly 10 g/L after 2 weeks. Dose changes should be based on the full CBC and iron profile, not RDW alone.

When should ferritin be checked after iron therapy?

For many adults on oral iron, a CBC is repeated after about 2-4 weeks to confirm a haemoglobin response, while ferritin is often checked after 8-12 weeks or after haemoglobin correction. Ferritin measured soon after intravenous iron can be artificially high and may not represent stable long-term stores. A ferritin below 15 µg/L strongly supports depleted stores in a well adult, but infection and inflammation can raise ferritin independently of iron availability. Transferrin saturation below 20% and CRP can clarify an ambiguous result.

Get AI-Powered Blood Test Analysis Today

Join over 2 million users worldwide who trust Kantesti for instant, accurate lab test analysis. Upload your blood test results and receive comprehensive interpretation of 15,000+ biomarkers in seconds.

📚 Referenced Research Publications

1

Klein, T., Mitchell, S., & Weber, H. (2026). Multilingual AI Assisted Clinical Decision Support for Early Hantavirus Triage: Design, Engineering Validation, and Real-World Deployment Across 50,000 Interpreted Blood Test Reports. Kantesti AI Medical Research.

2

Klein, T., Mitchell, S., & Weber, H. (2026). A Pre-Registered, Rubric-Based Automated Technical Benchmark of the Kantesti Blood-Test Interpretation Engine on 100,000 Synthetic Test Cases. Kantesti AI Medical Research.

📖 External Medical References

3

Snook J et al. (2021). British Society of Gastroenterology guidelines for the management of iron deficiency anaemia in adults. Gut.

4

Ko CW et al. (2020). AGA Clinical Practice Guidelines on the Gastrointestinal Evaluation of Iron Deficiency Anemia. Gastroenterology.

5

Camaschella C (2015). Iron-Deficiency Anemia. New England Journal of Medicine.

2M+Tests Analyzed
127+Countries
75+Languages

⚕️ Medical Disclaimer

E-E-A-T Trust Signals

Experience

Physician-led clinical review of lab interpretation workflows.

📋

Expertise

Laboratory medicine focus on how biomarkers behave in clinical context.

👤

Authoritativeness

Written by Dr. Thomas Klein with review by Dr. Sarah Mitchell and Prof. Dr. Hans Weber.

🛡️

Trustworthiness

Evidence-based interpretation with clear follow-up pathways to reduce alarm.

🏢 Kantesti LTD Registered in England & Wales · Company No. 17090423 London, United Kingdom · kantesti.net
blank
By Prof. Dr. Thomas Klein

Dr. Thomas Klein is a board-certified clinical hematologist serving as Chief Medical Officer at Kantesti AI. With over 15 years of experience in laboratory medicine and a strong interest in AI-supported interpretation of blood test results, he works to connect new technology with everyday clinical practice. His areas of interest include biomarker analysis, clinical decision support research and population-specific reference range optimization. As CMO, he contributes clinical input to the platform's internal benchmarking and provides clinical oversight for the medical quality of Kantesti's educational reports.

Leave a Reply

Your email address will not be published. Required fields are marked *